Japan-based food and ingredients group Ajinomoto has snapped up US medical foods supplier Cambrooke Therapeutics from investors Galen Partners and Seventure Partners.

Massachusetts-based Cambrooke, set up in 2000, makes medical formulas and food for people with “chronic health conditions”, Ajinomoto said. The financial details of the transaction were not disclosed.

Ajinomoto said it had been eyeing a number of companies to help it grow in the medical nutrition sector, an area blue-chip multinationals including Nestle and Danone already do business.

“We looked at many companies in recent years to help us grow in medical nutrition. The team at Cambrooke has been very successful in growing faster than other companies by better meeting the nutritional needs of the customers they serve,” Tatsuya Sato, the president of Ajinomoto’s business in North America, said.

Howard Lossing, Cambrooke’s president and CEO, said the US business would benefit from Ajinomoto’s research and development.

“In joining the Ajinomoto Group, our mission remains unchanged, our team remains in place, and our ability to better meet the needs of our customers expands with access to the enormous R&D capabilities of Ajinomoto,” Lossing said.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Cambrooke was set up at the turn of the century by Lynn and David Paolella, the parents of two children diagnosed with a rare genetic disease called phenylketonuria (PKU). PKU is one of the few genetic diseases managed almost entirely with nutritional intervention.

Co-founder Lynn Paolella said: “I have been developing specialty low protein products and medical foods for over 20 years, as well as preparing meals at home for my two children with phenylketonuria (PKU). Adding Ajinomoto’s ingredient, flavour and nutrition know-how to Cambrooke’s growing family of products makes the future brighter for all families touched by chronic health conditions.”